HCW BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 USD | -4.12% |
|
-8.50% | +14.28% |
| 01/04 | HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01/04 | HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 52.95M 4.41B |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -1.92B | Net income 2025 * | -29M -2.42B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.46
x | P/E ratio 2025 * |
-2.55
x | Employees | 45 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.07% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.12% | ||
| 1 week | -8.50% | ||
| Current month | -20.01% | ||
| 1 month | -20.46% | ||
| 3 months | +27.26% | ||
| 6 months | -12.51% | ||
| Current year | +14.28% |
1 week
1.35
1.64
1 month
1.351.93
Current year
1.101.93
1 year
0.912.32
3 years
0.917.78
5 years
0.917.78
10 years
0.917.78
| Managers | Title | Age | Since |
|---|---|---|---|
Hing Wong
FOU | Founder | 70 | 02/18/02 |
Rebecca Byam
DFI | Director of Finance/CFO | 68 | 01/19/01 |
Peter Rhode
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Scott Garrett
CHM | Chairman | 73 | 01/21/01 |
Hing Wong
FOU | Founder | 70 | 02/18/02 |
Rick Greene
BRD | Director/Board Member | 59 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.4 | -4.12% | 2,444 |
| 25/24/25 | 1.46 | -2.67% | 2,755 |
| 24/24/24 | 1.5 | -6.46% | 888 |
| 23/24/23 | 1.604 | -1.62% | 8,757 |
| 22/24/22 | 1.63 | +6.54% | 3,309 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.4
USD
Average target price
4
USD
Spread / Average Target
+185.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.28% | 52.95M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- HCWB Stock
